Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

NCT04976127 is registered in ClinicalTrials.gov with InnoMedica Schweiz AG as lead sponsor.

NCT NCT04976127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04976127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients
Lead sponsor
InnoMedica Schweiz AG
Phase
Phase 1
Overall status
Terminated
Start date
December 11, 2021
Completion date
August 6, 2025
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease